Breast cancer imaging devices

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Conventional mammography is a screening procedure constrained by low specificity in the detection of breast cancer. Approximately 40% of women undergoing mammography screening have dense breast tissue, and conventional mammographic imaging has a sensitivity range of only 50%-85% for malignant lesions. Magnetic resonance imaging (MRI) is now recommended for breast cancer screening in high-risk patients. However, approximately 15% of patients cannot tolerate MRI. These are the clinical situations in which positron emission mammography (PEM) and breast-specific gamma (BSG) camera systems fulfill a need for primary breast cancer imaging. Because breast cancer is the most common malignancy and the second most common cause of cancer death among women, many nuclear medicine imaging techniques are essential in the evaluation and therapy of patients with this disease. Nuclear medicine surgical techniques consist of sentinel lymph node localization and the use of radiolabeled seeds for intraoperative localization of nonpalpable breast cancers. The Food and Drug Administration (FDA) has approved the PEM Flex Solo II scanner, which has the capability for stereotactic biopsy, with an array of pixelated lutetium yttrium orthosilicate (LYSO) crystals, position-sensitive photomultiplier tubes (PS-PMT), and a spatial resolution of 2.4 mm. Clear PEM is a scanner in development with cerium-doped LYSO (LYSO:Ce) crystals, multipixel avalanche photodiodes, depth of interaction measurement with a resolution of 1.3 mm. The Dilon 6800 Gamma Camera is a BSG device approved by the FDA with stereotactic biopsy guidance capability, a pixelated array of sodium iodide crystals, PS-PMTs, and an extrinsic spatial resolution of 6 mm at 3 cm from the camera. GE has just received clearance from the FDA for a molecular breast imaging camera, the Discovery NM 750b, with pixelated cadmium zinc telluride crystals, semiconductor photoelements and an extrinsic resolution of 3.5 mm at 3 cm. The Society of Nuclear Medicine has issued guidelines for BSG camera image interpretation recommendations and clinical indications. Different crystals and camera architectures are under investigation to further improve resolution for both PEM and BSG imaging.

Original languageEnglish (US)
Pages (from-to)229-241
Number of pages13
JournalSeminars in Nuclear Medicine
Volume41
Issue number3
DOIs
StatePublished - May 2011
Externally publishedYes

Fingerprint

Mammography
Breast
Breast Neoplasms
Equipment and Supplies
Gamma Cameras
United States Food and Drug Administration
Electrons
Nuclear Medicine
Magnetic Resonance Imaging
Avalanches
Sodium Iodide
Cerium
Biopsy
Yttrium
Semiconductors
Molecular Imaging
Second Primary Neoplasms
Early Detection of Cancer
Cause of Death
Seeds

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Breast cancer imaging devices. / Moadel, Renee M.

In: Seminars in Nuclear Medicine, Vol. 41, No. 3, 05.2011, p. 229-241.

Research output: Contribution to journalArticle

@article{82ec1002ad9445648409b4a151e76cbe,
title = "Breast cancer imaging devices",
abstract = "Conventional mammography is a screening procedure constrained by low specificity in the detection of breast cancer. Approximately 40{\%} of women undergoing mammography screening have dense breast tissue, and conventional mammographic imaging has a sensitivity range of only 50{\%}-85{\%} for malignant lesions. Magnetic resonance imaging (MRI) is now recommended for breast cancer screening in high-risk patients. However, approximately 15{\%} of patients cannot tolerate MRI. These are the clinical situations in which positron emission mammography (PEM) and breast-specific gamma (BSG) camera systems fulfill a need for primary breast cancer imaging. Because breast cancer is the most common malignancy and the second most common cause of cancer death among women, many nuclear medicine imaging techniques are essential in the evaluation and therapy of patients with this disease. Nuclear medicine surgical techniques consist of sentinel lymph node localization and the use of radiolabeled seeds for intraoperative localization of nonpalpable breast cancers. The Food and Drug Administration (FDA) has approved the PEM Flex Solo II scanner, which has the capability for stereotactic biopsy, with an array of pixelated lutetium yttrium orthosilicate (LYSO) crystals, position-sensitive photomultiplier tubes (PS-PMT), and a spatial resolution of 2.4 mm. Clear PEM is a scanner in development with cerium-doped LYSO (LYSO:Ce) crystals, multipixel avalanche photodiodes, depth of interaction measurement with a resolution of 1.3 mm. The Dilon 6800 Gamma Camera is a BSG device approved by the FDA with stereotactic biopsy guidance capability, a pixelated array of sodium iodide crystals, PS-PMTs, and an extrinsic spatial resolution of 6 mm at 3 cm from the camera. GE has just received clearance from the FDA for a molecular breast imaging camera, the Discovery NM 750b, with pixelated cadmium zinc telluride crystals, semiconductor photoelements and an extrinsic resolution of 3.5 mm at 3 cm. The Society of Nuclear Medicine has issued guidelines for BSG camera image interpretation recommendations and clinical indications. Different crystals and camera architectures are under investigation to further improve resolution for both PEM and BSG imaging.",
author = "Moadel, {Renee M.}",
year = "2011",
month = "5",
doi = "10.1053/j.semnuclmed.2010.12.005",
language = "English (US)",
volume = "41",
pages = "229--241",
journal = "Seminars in Nuclear Medicine",
issn = "0001-2998",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Breast cancer imaging devices

AU - Moadel, Renee M.

PY - 2011/5

Y1 - 2011/5

N2 - Conventional mammography is a screening procedure constrained by low specificity in the detection of breast cancer. Approximately 40% of women undergoing mammography screening have dense breast tissue, and conventional mammographic imaging has a sensitivity range of only 50%-85% for malignant lesions. Magnetic resonance imaging (MRI) is now recommended for breast cancer screening in high-risk patients. However, approximately 15% of patients cannot tolerate MRI. These are the clinical situations in which positron emission mammography (PEM) and breast-specific gamma (BSG) camera systems fulfill a need for primary breast cancer imaging. Because breast cancer is the most common malignancy and the second most common cause of cancer death among women, many nuclear medicine imaging techniques are essential in the evaluation and therapy of patients with this disease. Nuclear medicine surgical techniques consist of sentinel lymph node localization and the use of radiolabeled seeds for intraoperative localization of nonpalpable breast cancers. The Food and Drug Administration (FDA) has approved the PEM Flex Solo II scanner, which has the capability for stereotactic biopsy, with an array of pixelated lutetium yttrium orthosilicate (LYSO) crystals, position-sensitive photomultiplier tubes (PS-PMT), and a spatial resolution of 2.4 mm. Clear PEM is a scanner in development with cerium-doped LYSO (LYSO:Ce) crystals, multipixel avalanche photodiodes, depth of interaction measurement with a resolution of 1.3 mm. The Dilon 6800 Gamma Camera is a BSG device approved by the FDA with stereotactic biopsy guidance capability, a pixelated array of sodium iodide crystals, PS-PMTs, and an extrinsic spatial resolution of 6 mm at 3 cm from the camera. GE has just received clearance from the FDA for a molecular breast imaging camera, the Discovery NM 750b, with pixelated cadmium zinc telluride crystals, semiconductor photoelements and an extrinsic resolution of 3.5 mm at 3 cm. The Society of Nuclear Medicine has issued guidelines for BSG camera image interpretation recommendations and clinical indications. Different crystals and camera architectures are under investigation to further improve resolution for both PEM and BSG imaging.

AB - Conventional mammography is a screening procedure constrained by low specificity in the detection of breast cancer. Approximately 40% of women undergoing mammography screening have dense breast tissue, and conventional mammographic imaging has a sensitivity range of only 50%-85% for malignant lesions. Magnetic resonance imaging (MRI) is now recommended for breast cancer screening in high-risk patients. However, approximately 15% of patients cannot tolerate MRI. These are the clinical situations in which positron emission mammography (PEM) and breast-specific gamma (BSG) camera systems fulfill a need for primary breast cancer imaging. Because breast cancer is the most common malignancy and the second most common cause of cancer death among women, many nuclear medicine imaging techniques are essential in the evaluation and therapy of patients with this disease. Nuclear medicine surgical techniques consist of sentinel lymph node localization and the use of radiolabeled seeds for intraoperative localization of nonpalpable breast cancers. The Food and Drug Administration (FDA) has approved the PEM Flex Solo II scanner, which has the capability for stereotactic biopsy, with an array of pixelated lutetium yttrium orthosilicate (LYSO) crystals, position-sensitive photomultiplier tubes (PS-PMT), and a spatial resolution of 2.4 mm. Clear PEM is a scanner in development with cerium-doped LYSO (LYSO:Ce) crystals, multipixel avalanche photodiodes, depth of interaction measurement with a resolution of 1.3 mm. The Dilon 6800 Gamma Camera is a BSG device approved by the FDA with stereotactic biopsy guidance capability, a pixelated array of sodium iodide crystals, PS-PMTs, and an extrinsic spatial resolution of 6 mm at 3 cm from the camera. GE has just received clearance from the FDA for a molecular breast imaging camera, the Discovery NM 750b, with pixelated cadmium zinc telluride crystals, semiconductor photoelements and an extrinsic resolution of 3.5 mm at 3 cm. The Society of Nuclear Medicine has issued guidelines for BSG camera image interpretation recommendations and clinical indications. Different crystals and camera architectures are under investigation to further improve resolution for both PEM and BSG imaging.

UR - http://www.scopus.com/inward/record.url?scp=79953221149&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953221149&partnerID=8YFLogxK

U2 - 10.1053/j.semnuclmed.2010.12.005

DO - 10.1053/j.semnuclmed.2010.12.005

M3 - Article

VL - 41

SP - 229

EP - 241

JO - Seminars in Nuclear Medicine

JF - Seminars in Nuclear Medicine

SN - 0001-2998

IS - 3

ER -